The health-focused news outlet STAT on Tuesday published a bombshell report that suggests President Donald Trump may have used his position of power to obtain a powerful new obesity drug not yet approved by the Food and Drug Administration. According to the report, the FDA in April allowed one 79-year-old man to obtain Eli Lilly’s retatrutide, an experimental weight-loss drug, through a “compassionate use” waiver.